Signaling mechanisms that link salt retention to hypertension: Endogenous ouabain, the Na+ pump, the Na+/Ca2+ exchanger and TRPC proteins

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 12, 2010, Pages 1219-1229

  Blaustein, Mordecai P ^a   Hamlyn, John M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Receptor operated channel; Salt dependent hypertension; Sodium pump; Sodium calcium exchanger

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CALCIUM CHANNEL; CARDENOLIDE; DIGOXIN; OUABAIN; SODIUM CALCIUM EXCHANGE PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

ARTERY CONSTRICTION; ARTERY MUSCLE; BLOOD VESSEL TONE; CHEMICAL STRUCTURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; SODIUM RETENTION;

ADRENAL CORTEX; ANIMALS; BLOOD PRESSURE; CALCIUM SIGNALING; CARDIOTONIC AGENTS; DIGOXIN; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; ION TRANSPORT; KIDNEY; MYOCYTES, SMOOTH MUSCLE; OUABAIN; PITUITARY GLAND; SODIUM; SODIUM-CALCIUM EXCHANGER; SODIUM-POTASSIUM-EXCHANGING ATPASE; STRUCTURE-ACTIVITY RELATIONSHIP; TRPC CATION CHANNELS;

STROPHANTHUS GRATUS;

EID: 78049238578     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.02.011     Document Type: Review

References (209)

1. Whitworth J.A. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003, 21:1983-1992.
2. Koeppen B.M., Stanton B.A. Renal Physiology 2001, 50. Mosby.
3. Campese V.M., Mitra N., Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment?. Kidney Int. 2006, 69:967-973.
4. N.M. Kaplan, Kaplan's Clinical Hypertension, 9th Ed., Lippincott Williams & Wilkins, Philadelphia, 2002, pp. 1-24, 36-135.
5. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms of human hypertension. Cell 2001, 104:545-556.
6. Lifton R.P. Genetic dissection of human blood pressure variation: common pathways from rare phenotypes. Harvey Lect. 2004-2005, 100:71-101.
7. Newhouse S.J., Wallace C., Dobson R., Mein C., Pembroke J., Farrall M., Clayton D., Brown M., Samani N., Dominiczak A., Connell J.M., Webster J., Lathrop G.M., Caulfield M., Munroe P.B. Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British Genetics of Hypertension study. Hum. Mol. Genet. 2005, 14:1805-1814.
8. Curtis J.J., Luke R.G., Dustan H.P., Kashgarian M., Whelchel J.D., Jones P., Diethelm A.G. Remission of essential hypertension after renal transplantation. N. Engl. J. Med. 1983, 309:1009-1015.
9. Guidi E., Menghetti D., Milani S., Montagnino G., Palazzi G., Bianchi G. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. J. Am. Soc. Nephrol. 1996, 7:1131-1138.
10. Rettig R., Grisk O. The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. Hypertension 2005, 46:463-468.
11. Cowley A.W.J. Long-term regulation of arterial blood pressure. Physiol. Rev. 1992, 72:231-300.
12. Guyton A.C. Blood pressure control-special role of the kidneys and body fluids. Science 1991, 252:1813-1816.
13. Guyton A.C., Jones C.E., Coleman T.G. Circulatory Physiology Cardiac Output and its Regulation 1973, Saunders, Philadelphia, PA.
14. Meneton P., Jeunemaitre X., de Wardener H.E., MacGregor G.A. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol. Rev. 2005, 85:679-715.
15. Weinberger M.H. Salt sensitivity of blood pressure in humans. Hypertension 1996, 27:481-490.
16. Guyton A.C., Coleman T.G. Quantitative analysis of the pathophysiology of hypertension. Circ. Res. 1969, 24(5 Suppl):1-19.
17. Guyton A.C., Coleman T.G., Cowley A.V.J., Scheel K.W., Manning R.D.J., Norman R.A.J. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am. J. Med. 1872, 52:584-594.
18. Norman R.A., Coleman T.G., Wiley T.L., Manning R.D., Guyton A.C. Separate roles of sodium ion concentration and fluid volumes in salt-loading hypertension in sheep. Am. J. Physiol. 1975, 229:1068-1072.
19. Freis E.D. Mechanism of the antihypertensive effects of diuretics. Possible role of salt in hypertension. Clin. Pharmacol. Ther. 1960, 1:337-344.
20. Rinehart J., Kahle K.T., de Los Heros P., Vazquez N., Meade P., Wilson F.H., Hebert S.C., Gimenez I., Gamba G., Lifton R.P. WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16777-16782.
21. Hamlyn J.M., Blaustein M.P. Sodium chloride, extracellular fluid volume, and blood pressure regulation. Am. J. Physiol. 1986, 251:F563-F575.
22. Ji W., Foo J.N., O'Roak B.J., Zhao H., Larson M.G., Simon D.B., Newton-Cheh C., State M.W., Levy D., Lifton R.P. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet. 2008, 40:592-599.
23. Johnson R.J., Rodriguez-Iturbe B., Nakagawa T., Kang D.H., Feig D.I., Herrera-Acosta J. Subtle renal injury is likely a common mechanism for salt-sensitive essential hypertension. Hypertension 2005, 45:326-330.
24. Davy K.P., Hall J.E. Obesity and hypertension: two epidemics or one. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286:R803-R813.
25. Hall J.E. The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
26. Zeng C., Sanada H., Watanabe H., Eisner G.M., Felder R.A., Jose P.A. Functional genomics of the dopaminergic system in hypertension. Physiol. Genomics 2004, 19:233-246.
27. Felder R.A., Sanada H., Xu J., Yu P.Y., Wang Z., Watanabe H., Asico L.D., Wang W., Zheng S., Yamaguchi I., Williams S.M., Gainer J., Brown N.J., Hazen-Martin D., Wong L.J., Robillard J.E., Carey R.M., Eisner G.M., Jose P.A. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3872-3877.
28. Zeng C., Eisner G.M., Felder R.A., Jose P.A. Dopamine receptor and hypertension. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2005, 3:69-77.
29. Bianchi G., Ferrari P., Staessen J.A. Adducin polymorphism: detection and impact on hypertension and related disorders. Hypertension 2005, 45:331-340.
30. Lanzani C., Citterio L., Jankaricova M., Sciarrone M.T., Barlassina C., Fattori S., Messaggio E., Serio C.D., Zagato L., Cusi D., Hamlyn J.M., Stella A., Bianchi G., Manunta P. Role of the adducin family genes in human essential hypertension. J. Hypertens. 2005, 23:543-549.
31. Wang Y., O'Connell J.R., McArdle P.F., Wade J.B., Dorff S.E., Shah S.J., Shi X., Pan L., Rampersaud E., Shen H., Kim J.D., Subramanya A.R., Steinle N.I., Parsa A., Ober C.C., Welling P.A., Chakravarti A., Weder A.B., Cooper R.S., Mitchell B.D., Shuldiner A.R., Chang Y.P. From the cover: whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:226-231.
32. Schmidlin O., Sebastian A.F., Morris R.C. What initiates the pressor effect of salt in salt-sensitive humans? Observations in normotensive blacks. Hypertension 2007, 49:1032-1039.
33. Levy M.N., Pappano A.J. Cardiovascular Physiology 2007, Mosby Elsevier, Philadelphia, PA. 9th ed.
34. Davis M.J., Hill M.A. Signaling mechanisms underlying the vascular myogenic response. Physiol. Rev. 1999, 79:387-423.
35. 2+ signaling pathways underlying myogenic reactivity. J. Appl. Physiol. 2001, 91:973-983.
36. Zhang J., Lee M.Y., Cavalli M., Chen L., Berra-Romani R., Balke C.W., Bianchi G., Ferrari P., Hamlyn J.M., Iwamoto T., Lingrel J.B., Matteson D.R., Wier W.G., Blaustein M.P. Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice. J. Physiol. 2005, 569:243-256.
37. Payne R.A., Webb D.J. Arterial blood pressure and stiffness in hypertension: is arterial structure important?. Hypertension 2006, 48:366-367.
38. Schiffrin E.L. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am. J. Hypertens. 2004, 17:1192-1200.
39. Touyz R.M. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr. Opin. Nephrol. Hypertens. 2005, 14:125-131.
40. Feihl F., Liaudet L., Waeber B., Levy B.I. Hypertension: a disease of the microcirculation?. Hypertension 2006, 48:1012-1017.
41. Levy B.I., Ambrosio G., Pries A.R., Struijker-Boudier H.A. Microcirculation in hypertension: a new target for treatment?. Circulation 2001, 104:735-740.
42. Zhang J., Hamlyn J.M., Karashima E., Raina H., Mauban J.R., Izuka M., Berra-Romani R., Zulian A., Wier W.G., Blaustein M.P. Low-dose ouabain constricts small arteries from ouabain-hypertensive rats: implications for sustained elevation of vascular resistance. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1140-H1150.
43. Schmidlin O., Sebastian A.F., Morris R.C. What initiates the pressor effect of salt in salt-sensitive humans? Observations in normotensive blacks. Hypertension 2007, 49:1032-1039.
44. Bohr D.F., Dominiczak A.F., Webb R.C. Pathophysiology of the vasculature in hypertension. Hypertension 1991, 18:III69-III75.
45. Rüegg J.C. Calcium in Muscle Contraction: Cellular and Molecular Physiology 1992, 206-212. Springer-Verlag Berlin, Heidelberg. second edition ed.
46. Vanhoutte P.M., Mombouli J.V. Vascular endothelium: vasoactive mediators. Prog. Cardiovasc. Dis. 1996, 39:229-238.
47. Fukata Y., Amano M., Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 2001, 22:32-39.
48. Maguire J.J., Davenport A.P. Regulation of vascular reactivity by established and emerging GPCRs. Trends Pharmacol. Sci. 2005, 26:448-454.
49. 2+ signalling in rat arteries: ATP, noradrenaline and neuropeptide Y. Exp. Physiol. 2009, 94:31-37.
50. 2+ signaling in arterial myocytes. Am. J. Physiol. Cell Physiol. 2000, 278:C163-C173.
51. 2+ entry in purinergically stimulated aorta smooth muscle cells. Circ. Res. 2007, 101:1030-1038.
52. Blaustein M.P., Lederer W.J. Sodium/calcium exchange: its physiological implications. Physiol. Rev. 1999, 79:763-854.
53. Borst J.G., Borst-De Geus A. Hypertension explained by Starling's theory of circulatory homoeostasis. Lancet 1963, 1:677-682.
54. Coleman T.G., Guyton A.C. Hypertension caused by salt loading in the dog. 3. Onset transients of cardiac output and other circulatory variables. Circ. Res. 1969, 25:153-160.
55. Schalekamp M.A., Man in't Veld A.J., Wenting G.J. The second Sir George Pickering memorial lecture. What regulates whole body autoregulation?. J. Hypertens. 1985, 3:97-108.
56. Ledingham J.M., Cohen R.D. Changes in the extracellular fluid volume and cardiac output during the development of experimental renal hypertension. Can. Med. Assoc. J. 1964, 90:292-294.
57. Guyton A.C., Granger H.J., Coleman T.G. Autoregulation of the total systemic circulation and its relation to control of cardiac output and arterial pressure. Circ. Res. 1971, 28(Suppl 1):93-97.
58. Distler A., Just H.J., Philipp T. Studies on the mechanism of aldosterone-induced hypertension in man. Clin. Sci. Mol. Med. 1973, 45:743-750.
59. 2+ stores and responsiveness. Am. J. Physiol. Cell Physiol. 1993, 264:C1367-C1387.
60. Blaustein M.P. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am. J. Physiol. Cell Physiol. 1977, 232:C165-C173.
61. Haddy F.J., Overbeck H.W. The role of humoral agents in volume expanded hypertension. Life Sci. 1976, 19:935-947.
62. M.V. Pulina, A. Zulian, R. Berra-Romani, O. Beskina, A. Mazzocco-Spezzia, S.G. Baryshnikov, I. Papparella, J.M. Hamlyn, M.P. Blaustein, V.A. Golovina, Upregulation of Na+ and Ca2+ transporters in arterial smooth muscle from ouabain-induced hypertensive rats, Am J Physiol Heart Circ Physiol 298 H263-274.
63. Hamlyn J.M., Blaustein M.P., Bova S., DuCharme D.W., Harris D.W., Mandel F., Mathews W.R., Ludens J.H. Identification and characterization of a ouabain-like compound from human plasma. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:6259-6263.
64. Pitzalis M.V., Hamlyn J.M., Messaggio E., Iacoviello M., Forleo C., Romito R., de Tommasi E., Rizzon P., Bianchi G., Manunta P. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur. J. Heart Fail. 2006, 8:179-186.
65. Blaustein M.P., Zhang J., Chen L., Song H., Raina H., Kinsey S.P., Izuka M., Iwamoto T., Kotlikoff M.I., Lingrel J.B., Philipson K.D., Wier W.G., Hamlyn J.M. The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension. Hypertension 2009, 53:291-298.
66. Manunta P., Hamilton B.P., Hamlyn J.M. Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290:R553-R559.
67. Huang M., Hester R.L., Coleman T.G., Smith M.J., Guyton A.C. Development of hypertension in animals with reduced total peripheral resistance. Hypertension 1992, 20:828-833.
68. O'Connell D.P., Ragsdale N.V., Boyd D.G., Felder R.A., Carey R.M. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997, 29:115-122.
69. Hong B.-C., Kim S., Kim T.-S., Corey E.J. Synthesis and properties of several isomers of the cardioactive steroid ouabain. Tetrahedron Lett. 2006, 47(2006):2711-2715.
70. Huang B.S., Amin M.S., Leenen F.H. The central role of the brain in salt-sensitive hypertension. Curr. Opin. Cardiol. 2006, 21:295-304.
71. Murrell J.R., Randall J.D., Rosoff J., Zhao J.L., Jensen R.V., Gullans S.R., Haupert G.T. Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 2005, 112:1301-1308.
72. Yamada K., Goto A., Omata M. Adrenocorticotropin-induced hypertension in rats: role of ouabain-like compound. Am. J. Hypertens. 1997, 10:403-408.
73. Laredo J., Hamilton B.P., Hamlyn J.M. Secretion of endogenous ouabain from bovine adrenocortical cells: role of the zona glomerulosa and zona fasciculata. Biochem. Biophys. Res. Commun. 1995, 212:487-493.
74. Boulanger B.R., Lilly M.P., Hamlyn J.M., Laredo J., Shurtleff D., Gann D.S. Ouabain is secreted by the adrenal gland in awake dogs. Am. J. Physiol. 1993, 264:E413-E419.
75. Dostanic-Larson I., Van Huysse J.W., Lorenz J.N., Lingrel J.B. The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15845-15850.
76. Hamlyn J.M., Laredo J., Shah J.R., Lu Z.R., Hamilton B.P. 11-hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann. N. Y. Acad. Sci. 2003, 986:685-693.
77. Hamlyn J.M., Lu Z.R., Manunta P., Ludens J.H., Kimura K., Shah J.R., Laredo J., Hamilton J.P., Hamilton M.J., Hamilton B.P. Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin. Exp. Hypertens. 1998, 20:523-533.
78. Laredo J., Hamilton B.P., Hamlyn J.M. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 1994, 135:794-797.
79. Goto A., Yamada K., Hazama H., Uehara Y., Atarashi K., Hirata Y., Kimura K., Omata M. Ouabainlike compound in hypertension associated with ectopic corticotropin syndrome. Hypertension 1996, 28:421-425.
80. Lichtstein D., Steinitz M., Gati I., Samuelov S., Deutsch J., Orly J. Biosynthesis of digitalis-like compounds in rat adrenal cells: hydroxycholesterol as possible precursor. Life Sci. 1998, 62:2109-2126.
81. el-Masri M.A., Clark B.J., Qazzaz H.M., Valdes R. Human adrenal cells in culture produce both ouabain-like and dihydroouabain-like factors. Clin. Chem. 2002, 48:1720-1730.
82. Sophocleous A., Elmatzoglou I., Souvatzoglou A. Circulating endogenous digitalis-like factor(s) (EDLF) in man is derived from the adrenals and its secretion is ACTH-dependent. J. Endocrinol. Invest. 2003, 26:668-674.
83. Gooz M., Toth M., Vakkuri O., Gooz P., Smolka A.J., de Chatel R., Szalay K.S. Endogenous ouabain-like factor (OLF) secretion is modulated by nicotinic mechanisms in rat adrenocortical cells. Life Sci. 2004, 74:2111-2128.
84. Manunta P., Evans G., Hamilton B.P., Gans D., Reseau J., Hamlyn J.M. A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor. J. Hypertens. 1992, 10(Suppl. 4):827. Abstract.
85. Evans G., Manunta P., Hamlyn J.M., Hamilton B.P., Gann D.S. Ouabainoma: a new syndrome of endocrine hypertension caused by a ouabain-secreting cortical adenoma. Endocrine Society 75th Annual Meeting. Las Vegas, June 9-12, 1993, Abstract 961 1993, 291.
86. Li M., Wen C., Whitworth J.A. Hemodynamic effects of the Fab fragment of digoxin antibody (digibind) in corticotropin (ACTH)-induced hypertension. Am. J. Hypertens. 1997, 10:332-336.
87. Krep H., Price D.A., Soszynski P., Tao Q.F., Graves S.W., Hollenberg N.K. Volume sensitive hypertension and the digoxin-like factor. Reversal by a Fab directed against digoxin in DOCA-salt hypertensive rats. Am. J. Hypertens. 1995, 8:921-927.
88. Kaide J., Ura N., Torii T., Nakagawa M., Takada T., Shimamoto K. Effects of digoxin-specific antibody Fab fragment (Digibind) on blood pressure and renal water-sodium metabolism in 5/6 reduced renal mass hypertensive rats. Am. J. Hypertens. 1999, 12:611-619.
89. Pullen M.A., Brooks D.P., Edwards R.M. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids. J. Pharmacol. Exp. Ther. 2004, 310:319-325.
90. Manunta P., Rogowski A.C., Hamilton B.P., Hamlyn J.M. Ouabain-induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. J. Hypertens. 1994, 12:549-560.
91. Manunta P., Stella P., Rivera R., Ciurlino D., Cusi D., Ferrandi M., Hamlyn J.M., Bianchi G. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 1999, 34:450-456.
92. Pierdomenico S.D., Bucci A., Manunta P., Rivera R., Ferrandi M., Hamlyn J.M., Lapenna D., Cuccurullo F., Mezzetti A. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am. J. Hypertens. 2001, 14:44-50.
93. Rossi G., Manunta P., Hamlyn J.M., Pavan E., De Toni R., Semplicini A., Pessina A.C. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J. Hypertens. 1995, 13:1181-1191.
94. Mason D.T., Braunwald E. Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure. J. Clin. Invest. 1964, 43:532-543.
95. Schulte K.L., van Gemmeren D., Thiede H.M., Meyer-Sabellek W., Gotzen R., Distler A. Ouabain-induced elevation in forearm vascular resistance, calcium entry and alpha-adrenoceptor blockade, and release and removal of noradrenaline. J. Hypertens. Suppl. 1987, 5:S215-S218.
96. Robinson B.F., Phillips R.J., Wilson P.N., Chiodini P.L. Effect of local infusion of ouabain on human forearm vascular resistance and on response to potassium, verapamil and sodium nitroprusside. J. Hypertens. 1983, 1:165-169.
97. Yuan C.M., Manunta P., Hamlyn J.M., Chen S., Bohen E., Yeun J., Haddy F.J., Pamnani M.B. Long-term ouabain administration produces hypertension in rats. Hypertension 1993, 22:178-187.
98. Kurashina T., Kirchner K.A., Granger J.P., Patel A.R. Chronic sodium-potassium-ATPase inhibition with ouabain impairs renal haemodynamics and pressure natriuresis in the rat. Clin. Sci. (Lond) 1996, 91:497-502.
99. Manunta P., Hamilton J., Rogowski A.C., Hamilton B.P., Hamlyn J.M. Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin. Hypertens. Res. 2000, 23:S77-S85.
100. Huang B.S., Kudlac M., Kumarathasan R., Leenen F.H. Digoxin prevents ouabain and high salt intake-induced hypertension in rats with sinoaortic denervation. Hypertension 1999, 34:733-738.
101. Ferrandi M., Manunta P., Balzan S., Hamlyn J.M., Bianchi G., Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997, 30:886-896.
102. Ferrandi M., Manunta P., Rivera R., Bianchi G., Ferrari P. Role of the ouabain-like factor and Na-K pump in rat and human genetic hypertension. Clin. Exp. Hypertens. 1998, 20:629-639.
103. Takada T., Nakagawa M., Ura N., Kaide J., Yoshida H., Shimamoto K. Endogenous immunoreactive ouabain-like and digoxin-like factors in reduced renal mass hypertensive rats. Hypertens. Res. 1998, 21:193-199.
104. Sekihara H., Yazaki Y., Kojima T. Ouabain as an amplifier of mineralocorticoid-induced hypertension. Endocrinology 1992, 131:3077-3082.
105. +-ATPase alterations in ouabain and adducin-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290:R529-R535.
106. Ferrari P., Torielli L., Ferrandi M., Padoani G., Duzzi L., Florio M., Conti F., Melloni P., Vesci L., Corsico N., Bianchi G. PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J. Pharmacol. Exp. Therap. 1998, 285:83-94.
107. Anderson D.E., Fedorova O.V., Morrell C.H., Longo D.L., Kashkin V.A., Metzler J.D., Bagrov A.Y., Lakatta E.G. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294:R1248-R1254.
108. Hildebrandt D.A., Montani J.-P., Heath B.J., Granger J.P. Chronic ouabain (QUA) infusion alters systemic hemodynamics in normal dogs. FASEB J. 1999, 9:A297.
109. Pidgeon G.B., Lewis L.K., Yandle T.G., Richards A.M., Nicholls M.G. Endogenous ouabain, sodium balance and blood pressure. J. Hypertens. 1996, 14:169-171.
110. Rowland N.E. NaCl appetite in two strains of rat reported to be resistant to mineralocorticoid-induced hypertension. Physiol. Behav. 1998, 64:49-56.
111. Wang J., Tempini A., Schnyder B., Montani J.P. Regulation of blood pressure during long-term ouabain infusion in Long-Evans rats. Am. J. Hypertens. 1999, 12:423-426.
112. Blanco G., Mercer R.W. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am. J. Physiol. Ren. Physiol. 1998, 275:F633-F650.
113. Geering K. Subunit assembly and functional maturation of Na, K-ATPase. J. Membr. Biol. 1990, 115:109-121.
114. Geering K. Functional roles of Na, K-ATPase subunits. Curr. Opin. Nephrol. Hypertens. 2008, 17:526-532.
115. Dostanic-Larson I., Lorenz J.N., Van Huysse J.W., Neumann J.C., Moseley A.E., Lingrel J.B. The physiological role of the á1 and á2 isoforms of the Na, K-ATPase and biological significance of their cardiac glycoside binding site. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290(3):R524-R528.
116. Feraille E., Barlet-Bas C., Cheval L., Rousselot M., Carranza M.L., Dreher D., Arystarkhova E., Doucet A., Favre H. Presence of two isoforms of Na, K-ATPase with different pharmacological and immunological properties in the rat kidney. Pflugers Arch. 1995, 430:205-212.
117. + pump alpha subunit isoforms in plasmalemma. Physiological implications. Ann. N. Y. Acad. Sci. 1997, 834:524-536.
118. + pump low and high ouabain affinity alpha subunit isoforms are differently distributed in cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1800-1805.
119. Lingrel J.B., Orlowski J., Shull M.M., Price E.M. Molecular genetics of Na, K-ATPase. Prog. Nucleic Acid Res. Mol. Biol. 1990, 38:37-89.
120. +-ATPase localization and aldosterone regulation in mouse kidney cells. J. Physiol. 2004, 555:355-364.
121. Zahler R., Zhang Z.T., Manor M., Boron W.F. Sodium kinetics of Na, K-ATPase alpha isoforms in intact transfected HeLa cells. J. Gen. Physiol. 1997, 110:201-213.
122. Lencesova L., O'Neill A., Resneck W.G., Bloch R.J., Blaustein M.P. Plasma membrane-cytoskeleton-endoplasmic reticulum complexes in neurons and astrocytes. J. Biol. Chem. 2004, 279:2885-2893.
123. McGrail K.M., Phillips J.M., Sweadner K.J. Immunofluorescent localization of three Na, K-ATPase isozymes in the rat central nervous system: both neurons and glia can express more than one Na, K-ATPase. J. Neurosci. 1991, 11:381-391.
124. Moseley A.E., Lieske S.P., Wetzel R.K., James P.F., He S., Shelly D.A., Paul R.J., Boivin G.P., Witte D.P., Ramirez J.M., Sweadner K.J., Lingrel J.B. The Na, K-ATPase alpha 2 isoform is expressed in neurons, and its absence disrupts neuronal activity in newborn mice. J. Biol. Chem. 2003, 278:5317-5324.
125. Blaustein M.P., Juhaszova M., Golovina V.A., Church P.J., Stanley E.F. Na/Ca exchanger and PMCA localization in neurons and astrocytes: functional implications. Ann. N. Y. Acad. Sci. 2002, 976:356-366.
126. Cao C., Payne K., Lee-Kwon W., Zhang Z., Lim S.W., Hamlyn J., Blaustein M.P., Kwon H.M., Pallone T.L. Chronic ouabain treatment induces vasa recta endothelial dysfunction in the rat. Am. J. Physiol. Ren. Physiol. 2009, 296:F98-F106.
127. + pump alpha 2-isoform specifically couples to contractility in vascular smooth muscle: evidence from gene-targeted neonatal mice. Am. J. Physiol. Cell Physiol. 2004, 286:C813-C820.
128. James P.F., Grupp I.L., Grupp G., Woo A.L., Askew G.R., Croyle M.L., Walsh R.A., Lingrel J.B. Identification of a specific role for the Na, K-ATPase alpha 2 isoform as a regulator of calcium in the heart. Mol. Cell 1999, 3:555-563.
129. Lingrel J.B. Na, K-ATPase: isoform structure, function, and expression. J. Bioenerg. Biomembr. 1992, 24:263-270.
130. Lucking K., Nielsen J.M., Pedersen P.A., Jorgensen P.L. Na-K-ATPase isoform (alpha 3, alpha 2, alpha 1) abundance in rat kidney estimated by competitive RT-PCR and ouabain binding. Am. J. Physiol. 1996, 271:F253-F260.
131. O'Brien W.J., Lingrel J.B., Wallick E.T. Ouabain binding kinetics of the rat alpha two and alpha three isoforms of the sodium-potassium adenosine triphosphate. Arch. Biochem. Biophys. 1994, 310:32-39.
132. Withering W. An Account of the Foxglove and Some of its Medical Uses: With Practical Remarks on Dropsy and Other Diseases 1785, J and J Robinson, London.
133. Riegel R.E., Valvassori S.S., Elias G., Reus G.Z., Steckert A.V., de Souza B., Petronilho F., Gavioli E.C., Dal-Pizzol F., Quevedo J. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem. Int. 2009, 55:491-495.
134. Ashmore L.J., Hrizo S.L., Paul S.M., Van Voorhies W.A., Beitel G.J., Palladino M.J. Novel mutations affecting the Na, K ATPase alpha model complex neurological diseases and implicate the sodium pump in increased longevity. Hum. Genet. 2009, 126:431-447.
135. Stenkvist B. Is digitalis a therapy for breast carcinoma?. Oncol. Rep. 1999, 6:493-496.
136. Al-Ghoul M., Valdes R. Mammalian cardenolides in cancer prevention and therapeutics. Ther. Drug Monit. 2008, 30:234-238.
137. Newman R.A., Yang P., Pawlus A.D., Block K.I. Cardiac glycosides as novel cancer therapeutic agents. Mol. Interv. 2008, 8:36-49.
138. Winnicka K., Bielawski K., Bielawska A., Surazynski A. Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells. Biol. Pharm. Bull. 2008, 31:1131-1140.
139. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., Dang C.V., Liu J.O., Semenza G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19579-19586.
140. Simpson C.D., Mawji I.A., Anyiwe K., Williams M.A., Wang X., Venugopal A.L., Gronda M., Hurren R., Cheng S., Serra S., Zavareh R.B., Datti A., Wrana J.L., Ezzat S., Schimmer A.D. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res. 2009, 69:2739-2747.
141. Loreaux E.L., Kaul B., Lorenz J.N., Lingrel J.B. Ouabain-Sensitive alpha1 Na, K-ATPase enhances natriuretic response to saline load. J. Am. Soc. Nephrol. 2008, 19:1947-1954.
142. Nesher M., Dvela M., Igbokwe V.U., Rosen H., Lichtstein D. Physiological roles of endogenous ouabain in normal rats. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H2026-H2034.
143. Schoner W., Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 2007, 293:C509-C536.
144. Sweadner K.J. A third mode of ouabain signaling. Focus on, Regulation of ERK1/2 by ouabain and Na-K-ATPase-dependent energy utilization and AMPK activation in parotid acinar cells. Am. J. Physiol. Cell Physiol. 2008, 295:C588-C589.
145. Soltoff S.P., Hedden L. Regulation of ERK1/2 by ouabain and Na-K-ATPase-dependent energy utilization and AMPK activation in parotid acinar cells. Am. J. Physiol. Cell Physiol. 2008, 295:C590-C599.
146. Stoilov P., Lin C.H., Damoiseaux R., Nikolic J., Black D.L. A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11218-11223.
147. Tian J., Xie Z.J. The Na-K-ATPase and calcium-signaling microdomains. Physiology (Bethesda) 2008, 23:205-211.
148. Zhang S., Malmersjo S., Li J., Ando H., Aizman O., Uhlen P., Mikoshiba K., Aperia A. Distinct role of the N-terminal tail of the Na, K-ATPase catalytic subunit as a signal transducer. J. Biol. Chem. 2006, 281:21954-21962.
149. Schoner W., Scheiner-Bobis G. Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer. Semin. Nephrol. 2005, 25:343-351.
150. Li Z., Xie Z. The Na/K-ATPase/Src complex and cardiotonic steroid-activated protein kinase cascades. Pflugers Arch. 2009, 457:635-644.
151. Schatzmann H.J. Cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane. Helv. Physiol. Pharmacol. Acta 1953, 11:346-354.
152. Baker P.F., Blaustein M.P., Hodgkin A.L., Steinhardt R.A. The influence of calcium on sodium efflux in squid axons. J. Physiol. 1969, 200:431-458.
153. Langer G.A. Mechanism of action of the cardiac glycosides on the heart. Biochem. Pharmacol. 1981, 30:3261-3264.
154. Patnaik G.K., Dhawan B.N. Pharmacological investigations on asclepin-a new cardenolide from Asclepius curassavica. Part I: Cardiotonic activity and acute toxicity. Arzneimittelforschung 1978, 28:1095-1099.
155. Patnaik G.K., Kohler E. Pharmacological investigation on asclepin-a new cardenolide from Asclepias curassavica. Part II. Comparative studies on the inotropic and toxic effects of asclepin, g-strophantin, digoxin and digitoxin. Arzneimittelforschung 1978, 28:1368-1372.
156. Zucher W., Weiss-Berg E., Tamm C. 14-epi-digitoxigenin and 3-desoxydigitoxigenin. 19. Reactions with microorganisms. Helv. Chim. Acta 1969, 52:2449-2458.
157. Ragab M.S., Linde H.H.A., Meyer K. 14 β-Artebufogenin Ueber Kroetengifte, 29. Mitteilung Helvetica Chimica Acta 1962, 45:1794-1799.
158. Guntert T.W., Linde H.H.A. Chemistry and structure-activity relationships of cardioactive steroids. Cardiac Glycosides, Part 1 Experimental Pharmacology, vol. 56(1) 1981, 13-24. Springer Verlag, New York. K. Greef (Ed.).
159. Levinsky R.A., Lewis R.M., Bynum T.E., Hanley H.G. Digoxin induced intestinal vasoconstriction. The effects of proximal arterial stenosis and glucagon administration. Circulation 1975, 52:130-136.
160. Hess T., Scholtysik G., Salzmann R., Riesen W. Digoxin-specific antibody fragments and a calcium antagonist for reversal of digoxin-induced mesenteric vasoconstriction. J. Pharm. Pharmacol. 1983, 35:647-651.
161. Hulthen U.L., Bolli P., Kiowski W., Buhler F.R. Forearm vasoconstrictor response to ouabain: studies in patients with mild and moderate essential hypertension. J. Cardiovasc. Pharmacol. 1984, 6(Suppl 1):S75-S81.
162. Mecca T.E., Elam J.T., Caldwell R.W. Mechanism of the pulmonary vasoconstrictor action of digoxin in the dog. J. Cardiovasc. Pharmacol. 1985, 7:833-840.
163. Cooke J.P., Shepherd J.T., Vanhoutte P.M. Vasoconstriction induced by ouabain in the canine coronary artery: contribution of adrenergic and nonadrenergic responses. Cardiovasc. Drugs Ther. 1988, 2:255-263.
164. Indolfi C., Piscione F., Russolillo E., Villari B., Golino P., Ambrosini V., Condorelli M., Chiariello M. Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. Am. J. Cardiol. 1991, 68:1274-1278.
165. Blaustein M.P., Zhang J., Chen L., Hamilton B.P. How does salt retention raise blood pressure?. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290:R514-R523.
166. 2+ exchanger type-1 in vascular smooth muscle. Nat. Med. 2004, 10:1193-1199.
167. Bodemann H.H. The current concept for the cardiac glycoside receptor. Clin. Cardiol. 1981, 4:223-228.
168. Manunta P., Tyzack J., Hamilton B.P., Hamlyn J.M. Augmentation and antagonism of ouabain-induced hypertension. Hypertension 1993, 22:432.
169. Kimura K., Manunta P., Hamilton B.P., Hamlyn J.M. Different effects of in vivo ouabain and digoxin on renal artery function and blood pressure in the rat. Hypertens. Res. 2000, 23:S67-S76.
170. Wang H., Lu Z., Yuan W. Comparative study of the effects of ouabain and digoxin on blood pressure of rats. Chin. Med. J. (Engl) 1997, 110:911-914.
171. Gheorghiade M., van Veldhuisen D.J., Colucci W.S. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006, 113:2556-2564.
172. Abarquez R.F. Digitalis in the treatment of hypertension. A preliminary report. Acta Med. Philipp. 1967, 3:161-170.
173. Manunta P., Hamilton B.P., Hamlyn J.M. Structure-activity relationships for the hypertensinogenic activity of ouabain: role of the sugar and lactone ring. Hypertension 2001, 37:472-477.
174. Quadri L., Bianchi G., Cerri A., Fedrizzi G., Ferrari P., Gobbini M., Melloni P., Sputore S., Torri M. 17 beta-(3-furyl)-5 beta-androstane-3 beta, 14 beta, 17 alpha-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J. Med. Chem. 1997, 40:1561-1564.
175. Golovina V.A. Visualization of localized store-operated calcium entry in mouse astrocytes. Close proximity to the endoplasmic reticulum. J. Physiol. 2005, 564:737-749.
176. 2+ transporters in arterial smooth muscle from ouabain hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2009, 298:H263-H274.
177. Hofmann T., Obukhov A.G., Schaefer M., Harteneck C., Gudermann T., Schultz G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 1999, 397:259-263.
178. Harteneck C., Plant T.D., Schultz G. From worm to man: three subfamilies of TRP channels. Trends Neurosci. 2000, 23:159-166.
179. 2+ sensor. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13232-13237.
180. + pump alpha2 subunits to specialized plasma membrane microdomains. J. Biol. Chem. 2006, 281:12929-12940.
181. Somlyo A.V., Franzini-Armstrong C. New views of smooth muscle structure using freezing, deep-etching and rotary shadowing. Experientia 1985, 41:841-856.
182. +. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H679-H691.
183. Blaustein M.P., Juhaszova M., Golovina V.A. The cellular mechanism of action of cardiotonic steroids: a new hypothesis. Clin. Exp. Hypertens. 1998, 20:691-703.
184. Blaustein M.P., Wier W.G. Local sodium, global reach: filling the gap between salt and hypertension. Circ. Res. 2007, 101:959-961.
185. i homogeneity, and sarcoplasmic reticulum function in swine carotid artery. J. Physiol. 1998, 513(Pt 2):477-492.
186. Xin H.B., Deng K.Y., Rishniw M., Ji G., Kotlikoff M.I. Smooth muscle expression of Cre recombinase and eGFP in transgenic mice. Physiol. Genomics 2002, 10:211-215.
187. + ATPase in smooth muscle decreases blood pressure. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1172-H1182.
188. Ferrari P., Ferrandi M., Tripodi G., Torielli L., Padoani G., Minotti E., Melloni P., Bianchi G. PST 2238: a new antihypertensive compound that modulates Na, K-ATPase in genetic hypertension. J. Pharmacol. Exp. Ther. 1999, 288:1074-1083.
189. Dostanic I., Paul R.J., Lorenz J.N., Theriault S., Van Huysse J.W., Lingrel J.B. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H477-H485.
190. 2+ transport. Biochem. J. 2007, 406:365-382.
191. 2+ and contractility in arterial smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1226-H1235.
192. Quednau B.D., Nicoll D.A., Philipson K.D. The sodium/calcium exchanger family-SLC8. Pflugers Arch. 2004, 447:543-548.
193. 2+ exchanger and tissue-specific expression of isoforms. J. Biochem. (Tokyo) 1993, 114:528-534.
194. 2+ signaling. Am. J. Physiol. Cell Physiol. 2003, 284:C475-C486.
195. 2+ exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models. J. Pharmacol. Exp. Ther. 2001, 298:249-256.
196. 2+ exchange (NCX1) inhibition by SEA0400. J. Biol. Chem. 2004, 279:7544-7553.
197. 2+ exchanger is essential for the action of cardiac glycosides. Circ. Res. 2002, 90:305-308.
198. 2+ channel current and lowers blood pressure. Am J Physiol Heart Circ Physiol 2010, 298:H1472-H1483.
199. Wirth A., Benyo Z., Lukasova M., Leutgeb B., Wettschureck N., Gorbey S., Orsy P., Horvath B., Maser-Gluth C., Greiner E., Lemmer B., Schutz G., Gutkind J.S., Offermanns S. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat. Med. 2008, 14:64-68.
200. Wagner J., Drab M., Bohlender J., Amann K., Wienen W., Ganten D. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin. Exp. Hypertens. 1998, 20:205-221.
201. Seko T., Ito M., Kureishi Y., Okamoto R., Moriki N., Onishi K., Isaka N., Hartshorne D.J., Nakano T. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 2003, 92:411-418.
202. Bragulat E., de la Sierra A. Salt intake, endothelial dysfunction, and salt-sensitive hypertension. J. Clin. Hypertens. (Greenwich) 2002, 4:41-46.
203. Kunes J., Hojna S., Kadlecova M., Dobesova Z., Rauchova H., Vokurkova M., Loukotova J., Pechanova O., Zicha J. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol. Res. 2004, 53(Suppl 1):S23-S34.
204. Feletou M., Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H985-H1002.
205. Ponnuchamy B., Khalil R.A. Cellular mediators of renal vascular dysfunction in hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1001-R1018.
206. Gordon F.J., Mark A.L. Impaired baroreflex control of vascular resistance in prehypertensive Dahl S rats. Am. J. Physiol. 1983, 245:H210-H217.
207. Ferrari A.U., Gordon F.J., Mark A.L. Primary impairment of cardiopulmonary baroreflexes in Dahl salt-sensitive rats. J. Hypertens. Suppl. 1984, 2:S401-S403.
208. Miyajima E., Bunag R.D. Impaired sympathetic baroreflexes in prehypertensive Dahl hypertension-sensitive rats. Clin. Exp. Hypertens. 1986, 8:1049-1061.
209. Crowley S.D., Gurley S.B., Herrera M.J., Ruiz P., Griffiths R., Kumar A.P., Kim H.S., Smithies O., Le T.H., Coffman T.M. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17985-17990.